Financials in USD. Standardized financial statements.
A compact view of how Cannabis Bioscience International Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2010 | FY 2009 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $303,022 | $248,841 | $316,825 | $214,980 | $761,737 | $580,220 | $97,856 | $39,500 | $83.46M | $74.00M |
| Revenue Growth? | +21.8% | -21.5% | +47.4% | -71.8% | +31.3% | +492.9% | +147.7% | -100.0% | +12.8% | 0.0% |
| Cost of Revenue? | $40,106 | $45,599 | $93,450 | $46,763 | $3,644 | $0 | $0 | $0 | $56.69M | $56.12M |
| Gross Profit? | $262,916 | $203,242 | $223,375 | $168,217 | $758,092 | $580,220 | $97,856 | $39,500 | $26.77M | $17.87M |
| Gross Margin? | +86.8% | +81.7% | +70.5% | +78.2% | +99.5% | +100.0% | +100.0% | +100.0% | +32.1% | +24.2% |
| Operating Expenses? | $684,281 | $689,382 | $1.21M | $1.06M | $873,057 | $809,026 | $100,562 | $1.32M | $12.46M | $3.74M |
| Operating Income? | -$421,365 | -$486,140 | -$983,370 | -$888,060 | -$114,960 | -$228,810 | -$2,710 | -$1.28M | $14.31M | $14.14M |
| EBITDA? | -$335,529 | -$497,140 | -$905,228 | -$834,135 | -$111,320 | -$218,806 | -$2,706 | -$1.28M | $16.21M | -$11.25M |
| Income Before Tax | -$548,820 | -$651,346 | -$1.07M | -$885,171 | -$159,308 | -$226,463 | -$2,706 | -$1.28M | $14.21M | -$12.59M |
| Income Tax Expense | $0 | $0 | -$36,378 | $0 | $0 | $0 | $0 | $0 | $3.04M | $0 |
| Net Income? | -$548,820 | -$651,345 | -$1.03M | -$885,171 | -$159,308 | -$226,463 | -$2,706 | -$1.28M | $10.46M | -$13.43M |
| EPS? | $-0.05 | $-0.06 | $-0.10 | $-0.11 | $-0.02 | $-0.03 | $-0.00 | $-0.28 | $808.71 | $-1657.17 |
| Diluted EPS? | $-0.05 | $-0.06 | $-0.10 | $-0.11 | $-0.02 | $-0.03 | $-0.00 | $-0.28 | $808.71 | $-1657.17 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality